ATE454124T1 - Rekombinante anti-cd30-antikörper und deren verwendungen - Google Patents

Rekombinante anti-cd30-antikörper und deren verwendungen

Info

Publication number
ATE454124T1
ATE454124T1 AT01986050T AT01986050T ATE454124T1 AT E454124 T1 ATE454124 T1 AT E454124T1 AT 01986050 T AT01986050 T AT 01986050T AT 01986050 T AT01986050 T AT 01986050T AT E454124 T1 ATE454124 T1 AT E454124T1
Authority
AT
Austria
Prior art keywords
proteins
hodgkin
disease
antibodies
hefi
Prior art date
Application number
AT01986050T
Other languages
German (de)
English (en)
Inventor
Joseph Francisco
Grant Risdon
Alan Wahl
Clay Siegall
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24910311&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE454124(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Application granted granted Critical
Publication of ATE454124T1 publication Critical patent/ATE454124T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01986050T 2000-11-28 2001-11-28 Rekombinante anti-cd30-antikörper und deren verwendungen ATE454124T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/724,406 US7090843B1 (en) 2000-11-28 2000-11-28 Recombinant anti-CD30 antibodies and uses thereof
PCT/US2001/044811 WO2002043661A2 (en) 2000-11-28 2001-11-28 Recombinant anti-cd30 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
ATE454124T1 true ATE454124T1 (de) 2010-01-15

Family

ID=24910311

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01986050T ATE454124T1 (de) 2000-11-28 2001-11-28 Rekombinante anti-cd30-antikörper und deren verwendungen

Country Status (12)

Country Link
US (1) US7090843B1 (enExample)
EP (1) EP1347730B2 (enExample)
JP (1) JP4303964B2 (enExample)
AT (1) ATE454124T1 (enExample)
AU (2) AU3651802A (enExample)
CA (1) CA2430135C (enExample)
CY (1) CY1110700T1 (enExample)
DE (1) DE60141043D1 (enExample)
DK (1) DK1347730T4 (enExample)
ES (1) ES2339333T5 (enExample)
PT (1) PT1347730E (enExample)
WO (1) WO2002043661A2 (enExample)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040018194A1 (en) * 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
US20110313230A1 (en) 2001-05-11 2011-12-22 Terrance Grant Johns Specific binding proteins and uses thereof
CA2467242A1 (en) * 2001-11-20 2003-05-30 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
EP1461085A2 (en) * 2002-01-03 2004-09-29 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Immunoconjugates useful for treatment of tumours
KR100668538B1 (ko) * 2002-01-09 2007-01-16 메다렉스, 인코포레이티드 Cd30에 대한 인간 모노클로날 항체
US20070148171A1 (en) * 2002-09-27 2007-06-28 Xencor, Inc. Optimized anti-CD30 antibodies
CA2802205C (en) 2002-07-31 2016-01-19 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
CN103394083B (zh) 2003-11-06 2017-07-18 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
WO2006039644A2 (en) 2004-10-01 2006-04-13 Medarex, Inc. Methods of treating cd30 positive lymphomas
RU2492186C2 (ru) 2005-02-18 2013-09-10 Медарекс Ллс Выделенное анти-cd30 антитело (варианты), хозяйская клетка, способ получения химерного или гуманизированного варианта анти-cd30 антител (варианты), способ ингибирования роста клеток cd30+ и способ ингибирования роста опухолевых клеток, экспрессирующих cd30
CA2625998C (en) 2005-10-06 2015-12-01 Xencor, Inc. Optimized anti-cd30 antibodies
US8257706B2 (en) * 2006-08-25 2012-09-04 Seattle Genetics, Inc. CD30 binding agents and uses thereof
CA3160831A1 (en) 2007-07-16 2009-01-22 Genentech, Inc. Anti-cd79b antibodies and immunoconjugates and methods of use
CN101802013B (zh) 2007-07-16 2014-07-02 健泰科生物技术公司 人源化抗cd79b抗体和免疫偶联物及使用方法
EP2185188B1 (en) 2007-08-22 2014-08-06 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
JP5485897B2 (ja) 2007-10-12 2014-05-07 シアトル ジェネティクス,インコーポレーテッド 抗体−薬物複合体の併用療法
EP3269737B1 (en) 2008-01-31 2024-06-19 Genentech, Inc. Anti-cd79b antibodies and immunoconjugates and methods of use
DK2326350T3 (da) 2008-09-08 2013-12-16 Psma Dev Company L L C Forbindelser til at dræbe psma-udtrykkende, taxanresistente cancerceller
EP4378482A3 (en) 2009-01-09 2024-09-25 Seagen Inc. Dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
US20110076232A1 (en) 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
EP2629801B3 (en) 2010-10-22 2019-11-27 Seattle Genetics, Inc. Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway
WO2013092983A2 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides
KR102292840B1 (ko) * 2012-04-27 2021-08-25 노보 노르디스크 에이/에스 사람 cd30 리간드 항원 결합 단백질
WO2014009426A2 (en) 2012-07-13 2014-01-16 Innate Pharma Screening of conjugated antibodies
PL3342785T3 (pl) 2012-10-11 2020-09-07 Daiichi Sankyo Company, Limited Łączniki dla koniugatów przeciwciało-lek
WO2014061277A1 (ja) 2012-10-19 2014-04-24 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体-薬物コンジュゲート
EP3564259A3 (en) 2012-11-09 2020-02-12 Innate Pharma Recognition tags for tgase-mediated conjugation
JP6133431B2 (ja) 2012-11-24 2017-05-24 ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ.Hangzhou Dac Biotech Co.,Ltd. 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
CN108546283A (zh) 2012-12-21 2018-09-18 荷商台医(有限合伙)公司 亲水性自消耗连接子及其缀合物
US10611824B2 (en) 2013-03-15 2020-04-07 Innate Pharma Solid phase TGase-mediated conjugation of antibodies
MX2015012562A (es) 2013-03-15 2016-06-21 Abbvie Inc Purificacion de conjugados anticuerpo-farmaco (cafs).
HRP20190672T1 (hr) 2013-03-15 2019-08-23 AbbVie Deutschland GmbH & Co. KG Konjugirane formulacije anti-egfr protutijelo-lijek
US20160030384A1 (en) 2013-04-09 2016-02-04 Boston Biomedical, Inc. 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
EP3010547B1 (en) 2013-06-20 2021-04-21 Innate Pharma Enzymatic conjugation of polypeptides
JP6744212B2 (ja) 2013-06-21 2020-08-19 イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. ポリペプチドの酵素的結合
EP3756663A1 (en) 2013-10-15 2020-12-30 Seagen Inc. Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
MX2016009332A (es) 2014-01-29 2016-12-20 Shanghai hengrui pharmaceutical co ltd Conjugado de farmaco citotoxico-ligando, metodo de preparacion del mismo y uso del mismo.
CA2938919C (en) 2014-02-28 2020-12-29 Hangzhou Dac Biotech Co., Ltd Charged linkers and their uses for conjugation
ES2939760T3 (es) 2014-03-15 2023-04-26 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico para antígenos
US9950077B2 (en) 2014-06-20 2018-04-24 Bioalliance C.V. Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof
EP3160513B1 (en) 2014-06-30 2020-02-12 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
BR112017023576A2 (pt) 2014-09-23 2023-10-03 Genentech Inc Método para tratar uma disfunção proliferativa de células b
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
US12128069B2 (en) 2015-04-23 2024-10-29 The Trustees Of The University Of Pennsylvania Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
EP3636660A1 (en) 2015-05-30 2020-04-15 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
JP2018521979A (ja) 2015-06-03 2018-08-09 ボストン バイオメディカル, インコーポレイテッド 癌の治療に使用するための癌幹細胞性阻害剤および免疫療法剤を含む組成物
CA2989269C (en) 2015-06-15 2020-09-22 Robert Yongxin Zhao Hydrophilic linkers for conjugation of a cytotoxic agent or chromophore molecule to a cell-binding molecule
AU2015242213A1 (en) 2015-07-12 2018-03-08 Hangzhou Dac Biotech Co., Ltd Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
WO2017027392A1 (en) 2015-08-07 2017-02-16 Novartis Ag Treatment of cancer using chimeric cd3 receptor proteins
ES2987957T3 (es) 2015-11-23 2024-11-18 Novartis Ag Vectores de transferencia lentivirales optimizados y usos de los mismos
MX2018008106A (es) 2015-12-30 2019-03-14 Novartis Ag Terapias con celulas inmunoefectoras de una eficacia mejorada.
US10472422B2 (en) 2016-01-08 2019-11-12 Abgenomics International Inc. Tetravalent anti-PSGL-1 antibodies and uses thereof
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
EA201892040A1 (ru) 2016-03-25 2019-04-30 Сиэтл Дженетикс, Инк. Способ получения пегилированных соединений лекарственный препарат - линкер и их промежуточных соединений
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
EP3538221B1 (en) 2016-11-14 2024-10-09 Takeda Pharmaceutical Company Limited Pediatric human dosing of the anti-cd30 antibody-drug conjugate brentuximab vedotin
MX2019005583A (es) 2016-11-14 2019-10-21 Hangzhou Dac Biotech Co Ltd Vinculantes de conjugacion, conjugados de molecula de union a celulas que contienen los vinculantes, metodos de creacion y usos de dichos conjugados con los vinculantes.
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
CN106854245A (zh) * 2016-12-28 2017-06-16 无锡傲锐东源生物科技有限公司 抗cd30蛋白单克隆抗体及其用途
EP3574005B1 (en) 2017-01-26 2021-12-15 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
US20190375815A1 (en) 2017-01-31 2019-12-12 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
US20200048359A1 (en) 2017-02-28 2020-02-13 Novartis Ag Shp inhibitor compositions and uses for chimeric antigen receptor therapy
WO2018158716A1 (en) 2017-03-02 2018-09-07 Cadila Healthcare Limited Novel protein drug conjugate formulation
MX2019010769A (es) 2017-03-24 2019-12-11 Seattle Genetics Inc Proceso para la preparacion de enlazadores de farmacos de glucuronidos y compuestos intermediarios de los mismos.
JP2020520923A (ja) 2017-05-17 2020-07-16 ボストン バイオメディカル, インコーポレイテッド がんを処置するための方法
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
US11795229B2 (en) 2017-10-11 2023-10-24 Seattle Genetics, Inc. Methods of reducing side effects of anti-CD30 antibody drug conjugate therapy
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
KR20200069358A (ko) 2017-10-25 2020-06-16 노파르티스 아게 키메라 항원 수용체 발현 세포의 제조 방법
WO2019089798A1 (en) 2017-10-31 2019-05-09 Novartis Ag Anti-car compositions and methods
TW201922285A (zh) 2017-11-01 2019-06-16 美商西雅圖遺傳學公司 降低抗cd30抗體藥物綴合物療法之副作用之方法
CN117126279A (zh) 2018-03-20 2023-11-28 鸿运华宁(杭州)生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用
WO2019183438A1 (en) 2018-03-23 2019-09-26 Seattle Genetics, Inc. Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor
US20210047405A1 (en) 2018-04-27 2021-02-18 Novartis Ag Car t cell therapies with enhanced efficacy
WO2019213282A1 (en) 2018-05-01 2019-11-07 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
TW202519270A (zh) 2018-06-07 2025-05-16 美商思進公司 喜樹鹼結合物
EP3802825A1 (en) 2018-06-08 2021-04-14 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CA3155291A1 (en) 2018-09-24 2020-04-02 The Medical College Of Wisconsin, Inc. Anti-cd30 antibodies and methods of use
BR112021004656A2 (pt) 2018-09-26 2021-06-01 Jiangsu Hengrui Medicine Co., Ltd. conjugado fármaco-ligante de análogo exatecano, método para preparar o mesmo e aplicação do mesmo
JP2022502508A (ja) 2018-10-01 2022-01-11 シージェン・インコーポレーテッド 抗cd30抗体薬物複合体療法を使用して末梢性t細胞リンパ腫を処置する方法
CA3119467A1 (en) 2018-11-20 2020-05-28 Cornell University Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
ES3032659T3 (en) 2019-02-15 2025-07-23 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
AU2020222346B2 (en) 2019-02-15 2021-12-09 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US20220160771A1 (en) 2019-04-10 2022-05-26 Iulia Diaconu Flt3-specific chimeric antigen receptors and methods of using the same
AU2020347715A1 (en) 2019-09-18 2022-04-07 Systimmune, Inc. Camptothecin derivative and conjugate thereof
WO2021062122A1 (en) 2019-09-25 2021-04-01 Seagen Inc. Combination anti-cd30 adc, anti-pd-1 and chemotherapeutic for treatment of hematopoietic cancers
AU2020356955A1 (en) 2019-10-04 2022-04-14 Seagen Inc. Camptothecin peptide conjugates
WO2021067820A1 (en) 2019-10-04 2021-04-08 Seagen Inc. Formulation of antibody-drug conjugate
MX2022005240A (es) 2019-11-04 2022-08-19 Seagen Inc Conjugados de farmaco-anticuerpo anti-cd30 y su uso para el tratamiento de infeccion por vih.
BR112022011902A2 (pt) 2019-12-20 2022-09-06 Novartis Ag Terapias de combinação
TW202140078A (zh) 2020-01-22 2021-11-01 大陸商上海森輝醫藥有限公司 艾日布林衍生物的藥物偶聯物、其製備方法及其在醫藥上的應用
MX2022009389A (es) 2020-01-31 2022-10-13 Seagen Inc Conjugados de farmaco-anticuerpo anti-cd30 y su uso para el tratamiento de linfoma no hodgkin.
CN115103858B (zh) 2020-03-25 2025-07-15 江苏恒瑞医药股份有限公司 一种抗体药物偶联物的制备方法
MX2022011770A (es) 2020-03-25 2022-10-18 Jiangsu Hengrui Pharmaceuticals Co Ltd Composicion farmaceutica que contiene un conjugado de anticuerpo-farmaco y uso de la misma.
JP2023520930A (ja) 2020-04-10 2023-05-22 シージェン インコーポレイテッド 電荷多様性リンカー
US20230190949A1 (en) 2020-05-13 2023-06-22 Seagen Inc. Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates
US20230332104A1 (en) 2020-06-11 2023-10-19 Novartis Ag Zbtb32 inhibitors and uses thereof
CN115916199A (zh) 2020-06-23 2023-04-04 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
CN116134027B (zh) 2020-08-03 2025-01-24 诺华股份有限公司 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
BR112023014128A2 (pt) 2021-01-15 2023-10-31 Seagen Inc Conjugados de anticorpo-fármaco imunomodulatórios
IL305883A (en) 2021-03-18 2023-11-01 Seagen Inc Selective release of drugs from internalized conjugates of biologically active compounds
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
AU2022262600A1 (en) 2021-04-20 2023-10-05 Seagen Inc. Modulation of antibody-dependent cellular cytotoxicity
US20240384293A1 (en) 2021-04-27 2024-11-21 Novartis Ag Viral vector production system
KR20240015670A (ko) 2021-05-28 2024-02-05 씨젠 인크. 안트라사이클린 항체 접합체
KR20240099363A (ko) 2021-10-29 2024-06-28 씨젠 인크. 항-pd-1 항체와 항-cd30 항체-약물 접합체의 조합을 사용하여 암을 치료하는 방법
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
CN114891101B (zh) * 2021-12-02 2023-06-16 吉林省农业科学院 一种牛肌肉生长抑制素蛋白单克隆抗体及其应用
CA3254933A1 (en) 2022-03-17 2023-09-21 Seagen Inc. Camptothecin conjugates
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2023215740A1 (en) 2022-05-06 2023-11-09 Seagen Inc. Immunomodulatory antibody-drug conjugates
CN120076829A (zh) 2022-10-18 2025-05-30 明治制果药业株式会社 T细胞肿瘤的治疗剂
CN120112650A (zh) 2022-10-26 2025-06-06 诺华股份有限公司 慢病毒配制品
EP4634227A1 (en) 2022-12-13 2025-10-22 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
KR20260007569A (ko) 2023-03-22 2026-01-14 샐러브리스 바이오테라퓨틱스, 인크. 항-5t4 항원 결합 도메인, 항체-약물 접합체 및 이의 사용 방법
AU2024276994A1 (en) 2023-05-24 2025-10-23 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
TW202535940A (zh) 2023-10-24 2025-09-16 美商思進公司 化學治療化合物及使用方法
WO2025096626A1 (en) 2023-10-31 2025-05-08 Seagen Inc. Methods of treating cancers using anti-cd30 antibody-drug conjugates
WO2025149947A1 (en) 2024-01-12 2025-07-17 Seagen Inc. Antibody-drug conjugates
WO2025169056A1 (en) 2024-02-06 2025-08-14 Seagen Inc. Methods of treating cancers using anti-cd30 antibody-drug conjugates
CN119331093B (zh) * 2024-11-04 2025-07-11 武汉伊莱瑞特生物科技股份有限公司 一种抗CD30的兔源Fab抗体及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5165923A (en) * 1989-11-20 1992-11-24 Imperial Cancer Research Technology Methods and compositions for the treatment of hodgkin's disease
WO1991007437A2 (en) 1989-11-20 1991-05-30 Parker, David, L. Improved cd-30 antibodies and fragments thereof
DE4200043A1 (de) 1991-11-11 1993-05-13 Stein Harald Prof Dr Lymphoides cd30-antigen (ki-1), dessen protein- und die zugehoerige nucleotidsequenz, seine herstellung sowie mittel zur diagnose und untersuchung von tumoren
CA2110799A1 (en) 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
DK0615451T3 (da) 1992-05-26 2006-04-24 Immunex Corp Hidtil ukendt cytokin der binder til CD30
KR950703640A (ko) 1992-10-09 1995-09-20 가일 케이,나우톤. 간 보존 세포(liver reserve cells)
EP0678523B1 (en) 1993-01-14 2004-09-15 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Recombinant anti-hiv antibody and preparation thereof
JP3053873B2 (ja) * 1994-08-12 2000-06-19 イムノメディクス,インコーポレイテッド B細胞リンパ腫細胞および白血病細胞に特異的な免疫結合体およびヒト化抗体
DE69605181T3 (de) 1995-01-18 2006-08-24 Roche Diagnostics Gmbh Antikörper gegen cd30, die proteolytische spaltung und abgabe des membrangebundenen cd30 antigens verhindern
DE19543039C1 (de) 1995-11-08 1996-11-21 Medac Klinische Spezialpraep Rekombinante Liganden für das menschliche Zellmembran-Antigen CD30
DE19640733A1 (de) * 1996-10-02 1998-04-09 Abken Hinrich Verfahren zur Hemmung der unbegrenzten Profileration, Tumorbildung oder Metastasierung CD30 Antigen exprimierender Zellen
DE50112965D1 (de) 2000-04-22 2007-10-18 Pharmedartis Gmbh Apoptotika
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
CA2467242A1 (en) 2001-11-20 2003-05-30 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies

Also Published As

Publication number Publication date
DK1347730T4 (da) 2020-04-27
JP2005506035A (ja) 2005-03-03
EP1347730A2 (en) 2003-10-01
CA2430135A1 (en) 2002-06-06
AU3651802A (en) 2002-06-11
EP1347730B1 (en) 2010-01-06
WO2002043661B1 (en) 2003-03-06
EP1347730B2 (en) 2013-05-29
CA2430135C (en) 2012-10-02
US7090843B1 (en) 2006-08-15
JP4303964B2 (ja) 2009-07-29
ES2339333T5 (es) 2013-09-26
DK1347730T3 (da) 2010-02-01
AU2002236518B2 (en) 2006-10-26
PT1347730E (pt) 2010-03-03
WO2002043661A3 (en) 2003-01-16
CY1110700T1 (el) 2015-06-10
DE60141043D1 (de) 2010-02-25
ES2339333T3 (es) 2010-05-19
WO2002043661A2 (en) 2002-06-06
EP1347730A4 (en) 2005-08-17

Similar Documents

Publication Publication Date Title
ATE454124T1 (de) Rekombinante anti-cd30-antikörper und deren verwendungen
WO2005001038A3 (en) Recombinant anti-cd30 antibodies and uses thereof
US12527843B2 (en) Immune-cell targeted bispecific chimeric proteins and uses thereof
KR102486090B1 (ko) 생체 내 내성이 높은 항체 약물 결합체
WO2003043583A3 (en) Treatment of immunological disorders using anti-cd30 antibodies
BG108514A (en) METHODS OF ADMINISTERING ANTI-TNFalpha ANTIBODIES
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
EA200501810A1 (ru) Композиция конъюгированного лекарственного средства
TR200102733T2 (tr) IL-18 kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri
EA200000331A1 (ru) Фармацевтические композиции, содержащие белок плазмы
EP1921090A4 (en) COMPOSITION OF GENETICALLY MODIFIED ANTIBODY
ATE425181T1 (de) Therapeutische zusammensetzungen aus antikorper und antisens nukleinsäuren gegen serrate
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
MXPA03005273A (es) Anticuerpos producidos procarioticamente y sus usos.
DE69520739T2 (de) Konjugat aus einem modifizierten superantigen und einer zielsuchenden verbindung und die verwendung des konjugats
DE60028970D1 (de) An her2 bindende peptidverbindungen
WO2004066932A3 (en) Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
IL178474A0 (en) Monoclonal antibodies to hepatocyte growth factor and pharmaceutical compositions containing the same
WO1998057994A3 (en) Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
MXPA01008612A (es) Epitopos o mimotopos derivados de los dominos c-epsilon-3 o c-epsilon-4 de ige, antagonistas de los mismos y sus usos terapeuticos.
MXPA03011499A (es) Proteinas de fusion de fce para el tratamiento de alergia y asma.
ATE235551T1 (de) Ligand (tie ligand-4) vom tie-2 rezeptor und dessen verwendungen
WO2002100343A3 (en) N-terminally truncated galectin-3 and antibodies for treating cancer
HK1044004A1 (zh) 從ige的c-易扑西龍-2區衍生出的抗原決定基或者mimotope及其拮抗劑以及治療用途
WO2004100882A3 (en) Inhibition of drug binding to serum albumin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1347730

Country of ref document: EP